Yuhan Corporation Holds Pharmaceutical Industry's First 2025 Investment Day
Oct 02, 2025
Yuhan Corporation (CEO Cho Wook-je) announced on the 30th that it held '2025 Investment Day" for domestic and foreign institutional investors and investment industry workers at Yeouido Anchor One in Seoul with Yuanta Securities. The event was organized to share Yuhan's open innovation achievements and future strategies and visions, and to announce the business status and growth vision of five investee companies.
Participating companies are companies specializing in antibody-based immune anticancer drug development 'Emunncia', companies specializing in multi-target antibody technology 'Progen', companies specializing in improved new drug development 'Ad Pharma'Digital Healthcare leading company 'Huino', premium health & life solution based on natural product research 'Limited Health Life', and major executives of each company directly announced their business status and growth vision.
In the second part of the event, a 1:1 meeting between participating companies and investment industry workers introduced specific business conditions and strategies and conducted question-and-answer sessions.
Cho Wook-je, CEO of Yuhan Corporation, said "This event was a meaningful opportunity for our portfolio companies to communicate directly with key stakeholders in the investment industry beyond just public relations and introduce in-depth their business strategies and growth potential." In the future, Yuhan Corporation will continue to strengthen cooperation with related companies based on open innovation and create sustainable growth together, he stressed.
In addition, Luo Zifeng, CEO of Yuanta Securities, said, "We plan to continue to organize events such as limited investment day to strengthen cooperation with listed and non-listed companies, and to diversify our portfolio of corporate finance (IB) sectors. By securing diverse revenue sources without relying on specific sectors, Yuanta Securities will achieve stable and sustainable growth." he said.
Participating companies are companies specializing in antibody-based immune anticancer drug development 'Emunncia', companies specializing in multi-target antibody technology 'Progen', companies specializing in improved new drug development 'Ad Pharma'Digital Healthcare leading company 'Huino', premium health & life solution based on natural product research 'Limited Health Life', and major executives of each company directly announced their business status and growth vision.
In the second part of the event, a 1:1 meeting between participating companies and investment industry workers introduced specific business conditions and strategies and conducted question-and-answer sessions.
Cho Wook-je, CEO of Yuhan Corporation, said "This event was a meaningful opportunity for our portfolio companies to communicate directly with key stakeholders in the investment industry beyond just public relations and introduce in-depth their business strategies and growth potential." In the future, Yuhan Corporation will continue to strengthen cooperation with related companies based on open innovation and create sustainable growth together, he stressed.
In addition, Luo Zifeng, CEO of Yuanta Securities, said, "We plan to continue to organize events such as limited investment day to strengthen cooperation with listed and non-listed companies, and to diversify our portfolio of corporate finance (IB) sectors. By securing diverse revenue sources without relying on specific sectors, Yuanta Securities will achieve stable and sustainable growth." he said.
|
This article was translated by Naver AI translator.
